Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus ...
May 14, 2020 · A post hoc subgroup analysis of a recent large randomized phase III study of adjuvant chemotherapy in patients with pathologic stage IB-IIIA NSCLC (Eastern Cooperative …
Adjuvant chemotherapy with or without bevacizumab in patients …
Nov 9, 2017 · Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed …
Bevacizumab’s Association With a Decreased Risk of Brain …
ECOG-ACRIN E1505 was a phase 3 randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with stages IB (>4 cm) to IIIA NSCLC. We sought to estimate the …
Lung Cancer ECOG 1505 - Hartford HealthCare
Mar 13, 2013 · Lung Cancer ECOG 1505 . March 13, 2013. Location: The Hospital of Central Connecticut. A Phase III Randomized Trial of Adjuvant Chemotherapy with or without …
Cooperative Group Clinical Trials in General Thoracic Surgery: …
ecog 1505 A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (≥ 4 cm) to IIIA non-small cell lung cancer. ECOG …
Bevacizumab in the treatment of non-small-cell lung cancer
May 28, 2007 · A United States Intergroup trial, ECOG 1505, has been developed that will compare cisplatin-based therapy versus cisplatin-based therapy in combination with …
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG ...
Methods: The ECOG-ACRIN 1505 was conducted to determine whether the addition of bevacizumab to adjuvant chemotherapy would improve overall survival (OS) for patients with …
ECOG 1505 | CancerGRACE
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for …
Adjuvant chemotherapy with or without bevacizumab in patients …
Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to …
CTSU/E1505 - SWOG
Jul 1, 2007 · Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a phase III randomized trial of adjuvant chemotherapy with …